Prader-Willi syndrome (PWS) results from a deletion of the paternal genes in the region of chromosome 15q11-q13. PWS develops hyperphagia, which when left unmanaged, leads to an excessive ingestion of food. To date there is inadequate pharmacological treatment or supplementation for modification of the PWS hyperphagia and/or the associated behaviors. Therefore, the best practice is familial supervision and restriction of diet and environment. We aimed to determine if the natural supplement of Caralluma fimbriata extract (CFE) could attenuate hyperphagia or the associated appetite behaviors in children and adolescents with PWS over the 4-week pilot trial period. We conducted a placebo-controlled, double-blind, randomized crossover trial over a 10-week period to investigate the effects of CFE on hunger control, in a cohort of children and adolescents with confirmed PWS (n =15, mean age 9.27 ± 3.16 years, body weight 43.98 ± 23.99 kg). Participants from Australia and New Zealand ingested CFE or a placebo of maltodextrin/cabbage leaf over a 4-week period, with a 2-week washout before the crossover to the other treatment. Weekly comparisons in appetite behavior, severity, and drive were recorded by parents, as scaled time-point measures on a hyperphagia questionnaire validated for PWS. CFE administration was found to induce a significant accumulative easing of hyperphagia (P = 0.05), with decreases evident in one-third of the participants. Furthermore due to CFE supplementation, a significant decrease (P ≤ 0.05) was recorded in the category of behavior and a decrease in hyperphagia (n = 8, P = 0.009) was observed at the highest dose 1,000 mg/day (recommended adult dose). There were no reported adverse effects at any dose. We demonstrate that an extract of the Indian cactus succulent Caralluma fimbriata eases hyperphagic appetite behavior within a cohort of children and adolescents (n = 15) with PWS without notable adverse effects. The outcomes of this study will have a potential positive impact on PWS management.
Prader - Willi syndrome ( PWS ) results from a deletion of the paternal genes in the region of chromosome 15q11-q13 . PWS develops hyperphagia , which when left unmanaged , leads to an excessive ingestion of food . To date there is inadequate pharmacological treatment or supplementation for modification of the PWS hyperphagia and/or the associated behaviors . Therefore , the best practice is familial supervision and restriction of diet and environment . We aimed to determine if the natural supplement of Caralluma fimbriata extract ( CFE ) could attenuate hyperphagia or the associated appetite behaviors in children and adolescents with PWS over the 4-week pilot trial period . We conducted a placebo - controlled , double - blind , randomized crossover trial over a 10-week period to investigate the effects of CFE on hunger control , in a cohort of children and adolescents with confirmed PWS ( n = 15 , mean age 9.27 ± 3.16 years , body weight 43.98 ± 23.99 kg ) . Participants from Australia and New Zealand ingested CFE or a placebo of maltodextrin / cabbage leaf over a 4-week period , with a 2-week washout before the crossover to the other treatment . Weekly comparisons in appetite behavior , severity , and drive were recorded by parents , as scaled time - point measures on a hyperphagia questionnaire validated for PWS . CFE administration was found to induce a significant accumulative easing of hyperphagia ( P = 0.05 ) , with decreases evident in one - third of the participants . Furthermore due to CFE supplementation , a significant decrease ( P ≤ 0.05 ) was recorded in the category of behavior and a decrease in hyperphagia ( n = 8 , P = 0.009 ) was observed at the highest dose 1,000 mg / day ( recommended adult dose ) . There were no reported adverse effects at any dose . We demonstrate that an extract of the Indian cactus succulent Caralluma fimbriata eases hyperphagic appetite behavior within a cohort of children and adolescents ( n = 15 ) with PWS without notable adverse effects . The outcomes of this study will have a potential positive impact on PWS management .
Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?
Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15 , what is the disease ?
Prader-Willi syndrome
Prader-Willi syndrome